Frizziero L, Focherini M C, Valentini M, Reta M, Rocchi P
Unità Operativa di Reumatologia, Ospedale Maggiore, Bologna, Italy.
Minerva Med. 2002 Aug;93(4):315-20.
To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.
Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.
Thirty-four patients (28 F, 6 M) were admitted, mean age (+/- SD) 53.9+/-14.2 years, mean duration of illness 9.2+/-10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.
Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.
Zotero 插件